NEW BRUNSWICK, N.J., May 16 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) today reported financial results for the three months ended March 31, 2008.
Net loss for the three month period ended March 31, 2008 was $2.0
million, or $0.12 per share, compared with a net loss of $0.8 million, or
$0.05 per share, for the three month period ended March 31, 2007. This
increase in net loss was primarily the result of an increase of $0.8
million in expenses associated with the outstanding convertible notes that
were issued during the current fiscal year, and an increase in operating
Quarterly and Recent Highlights
-- Senesco regained compliance with AMEX's continued listing requirements.
-- Preclinical pancreatic islet cell research that was funded by the
Company was presented at two important industry conferences, the
Keystone Islet and Beta Cell Symposium, and the Upper Midwest Islet
Club's Annual Meeting. Using a small interfering RNA (siRNA) against
Senesco's Factor 5A technology, the data showed what Senesco believes
to be a variety of promising results regarding delivery of the
technology, as well as islet protection and function.
-- The Company announced the results of preclinical animal studies focused
on multiple myeloma. In the studies, mice were injected subcutaneously
with human multiple myeloma cancer cells to form myeloma tumors in
their flanks. Treated mice were injected intratumorally with Factor 5A
therapy encapsulated in nanoparticles, while control mice received a
nanoparticle without the Factor 5A therapy. One of the dosing regimens'/>"/>
|SOURCE Senesco Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved